

Form PTO-1595 (Rev. 06-12)
OMB No. 0651-0027 (exp. 04/30/2015)U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark Office**RECORDATION FORM COVER SHEET
PATENTS ONLY**

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)

Theravance, Inc.

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No**3. Nature of conveyance/Execution Date(s):**Execution Date(s) June 1, 2014

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Joint Research Agreement
☐ Government Interest Assignment
☐ Executive Order 9424, Confirmatory License
☐ Other _____

2. Name and address of receiving party(ies)Name: Theravance Biopharma R&D IP, LLC

Internal Address: _____

Street Address: 901 Gateway BoulevardCity: South San FranciscoState: CaliforniaCountry: USA Zip: 94080Additional name(s) & address(es) attached? ☐ Yes ☒ No**4. Application or patent number(s):**☐ This document serves as an Oath/Declaration (37 CFR 1.63).

A. Patent Application No.(s)

60903110, 14059755

B. Patent No.(s)

7834185, 8378121 and 8592453

Additional numbers attached? ☐ Yes ☒ No**5. Name and address to whom correspondence concerning document should be mailed:**Name: Jeffrey A. HagenahInternal Address: Patent Department
Theravance Biopharma US, Inc.Street Address: 901 Gateway BoulevardCity: South San FranciscoState: California Zip: 94080Phone Number: (650) 808-6406Docket Number: P-228Email Address: patent@theravance.com**6. Total number of applications and patents involved: 5****7. Total fee (37 CFR 1.21(h) & 3.41) \$200**

- ☒ Authorized to be charged to deposit account
☐ Enclosed
☐ None required (government interest not affecting title)

8. Payment InformationDeposit Account Number 500344Authorized User Name Jeffrey A. Hagenah**9. Signature:**Shelley Eberle

Signature

June 3, 2014

Date

Shelley Eberle, Reg. No. 31,411

Name of Person Signing

Total number of pages including cover sheet, attachments, and documents:

6

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
 Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

CH \$200.00 500344 60903110

Patent Assignment

WHEREAS, **Theravance, Inc.**, a corporation duly organized under and pursuant to the laws of Delaware and having its principal place of business at 951 Gateway Boulevard, South San Francisco, California 94080 (the "**Assignor**"), is the sole owner of the patents and patent applications listed in **EXHIBIT A** (such patents and patent applications and the inventions set forth therein are collectively the "**Assigned Patents**");

WHEREAS, **Theravance Biopharma R&D IP, LLC**, a limited liability company duly organized under and pursuant to the laws of Delaware and having its principal place of business at 901 Gateway Boulevard, South San Francisco, California 94080 (the "**Assignee**"), is desirous of acquiring Assignor's entire right, title and interest in and to the Assigned Patents, and in and to any subsequent patent applications and patents filed or granted thereon or therefrom, and Assignor is willing to assign its rights, title, and interest with respect thereto to the Assignee on the terms hereinafter set forth;

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged, the Assignor does hereby sell, assign, transfer, set over and relinquishes exclusively unto the Assignee, its successors, legal representatives and assigns, Assignor's entire right, title and interest in and to: the Assigned Patents including, to the extent of Assignor's rights, the right to file patent applications on inventions set forth in the Assigned Patents; the right to claim priority to any of the Assigned Patents; the entire right, title and interest in and to any subsequent U.S. and foreign patent applications and patents claiming priority to any of the Assigned Patents, and in and to any U.S. and foreign patent applications and patents that claim priority to a patent application or patent arising from the Assigned Patents; any U.S. and foreign patents that may be granted on and from any of the Assigned Patents; any applications, divisionals, continuations, continuations-in-part, reexaminations, reissues, registrations, renewals, revalidations, substitutions, utility models, petty patents, extensions, and supplementary protection certificates that may be filed or granted on or for any of the Assigned Patents; all accrued causes of action for infringement of any of the foregoing; and all rights to and for the Assigned Patents under the Paris Convention for the Protection of Industrial Property; the same to be held and enjoyed by the Assignee, for its own use and behalf and for the use and behalf of its successors, legal representatives and assigns, to the full end of the term of the Assigned Patents and any such patents that may be granted thereon or therefrom as fully and entirely as if the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives and assigns, that the Assignor has not executed and will not execute any assignment, sale, agreement or encumbrance in conflict with this assignment.


AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives and assigns that, at the Assignee's expense and reasonable request, the Assignor will take action and execute documents necessary to perfect the interest assigned herein.

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives and assigns that whenever counsel for the Assignee, or the counsel for its successors, legal representatives and assigns, shall advise that any proceeding, filing or other legal action in connection with the Assigned Patents or any patent applications and patents resulting therefrom is lawful and desirable, Assignor will, to the extent reasonable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of the Assigned Patents and patent applications and patents resulting therefrom, without charge to the Assignor, its successors, legal representatives and assigns, but at the cost and expense of the Assignee, its successors, legal representatives and assigns.

AND the Assignor hereby requests the Director of the United States Patent and Trademark Office, and all foreign patent offices, to issue any and all patents resulting from the Assigned Patents or from any patent applications filed thereon or therefrom to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives and assigns.

IN WITNESS WHEREOF, the Assignor hereby has executed this assignment on this 1st day of June 2014, at South San Francisco, California, USA.

Theravance, Inc. (Assignor)


Jeffrey A. Hagenah
Vice President & Chief Patent Counsel
& Assistant Secretary

Theravance, Inc.
951 Gateway Blvd.
South San Francisco, CA 94080
USA

Attorney Docket No. P-228

**CERTIFICATE OF
ACKNOWLEDGEMENT OF NOTARY PUBLIC**

**STATE OF CALIFORNIA
COUNTY OF SAN MATEO**

On June 1, 2014, before me, Maria Chuakay, Notary Public, personally appeared Jeffrey A. Hagenah, who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature Maria Chuakay (Seal)
Notary Public





EXHIBIT A

Docket No.	Country	Sub Case	Status	Application Number	Filing Date	Patent Number	Grant Date
P-228	AU	01	Granted	2008218962	02/21/2008	2008218962	06/25/2013
P-228	BR	01	Pending	0807615-4	02/21/2008		
P-228	CA	01	Pending	2,675,942	02/21/2008		
P-228	CN	01	Pending	200880005529.5	02/21/2008		
P-228	EP	01	Pending	08 725 911.5	02/21/2008		
P-228	HK	01	Pending	10103348.1	02/21/2008		
P-228	IL	01	Pending	199922	02/21/2008		
P-228	IN	01	Pending	4811/DELNP/2009	02/21/2008		
P-228	JP	01	Granted	2009-550918	02/21/2008	5528817	04/25/2014
P-228	JP	02	Pending	2014-33710	02/25/2014		
P-228	KR	01	Pending	2009-7019812	02/21/2008		
P-228	MX	01	Granted	MX/a/2009/008527	02/21/2008	301802	07/30/2012
P-228	RU	01	Granted	2009135389	02/21/2008	2452728	06/10/2012
P-228	SG	01	Granted	200905187-1	02/21/2008	154606	03/30/2012
P-228	US	01	Granted	12/070,780	02/21/2008	7,834,185	11/16/2010
P-228	US	02	Granted	12/898,858	10/06/2010	8,592,453	11/26/2013
P-228	US	03	Granted	12/898,861	10/06/2010	8,378,121	02/19/2013
P-228	US	04	Pending	14/059,755	10/22/2013		
P-228	US	PR1	Expired	60/903,110	02/23/2007		
P-228	WO		Nat Phase	PCT/US2008/002321	02/21/2008		

[Remainder of page intentionally left blank]

Facsimile Cover Sheet

For Transmission to the United States Patent and Trademark Office

To:	Mail Stop Assignment Recordation Services Director of the USPTO	
	Fax. No.	(571) 273-0140
From:	Theravance Biopharma US, Inc.	
	Attorney:	Shelley Eberle
	Reg. No. :	31,411
	Customer No.:	27038
	Address:	901 Gateway Boulevard South San Francisco, California 94080
	Telephone No.:	(650) 808-4010
	Fax. No.:	(650) 808-6078
Date:	June 3, 2014	
No. of Pages :	<u>6</u> (including this page)	
<u>Certificate of Facsimile Transmission</u> <i>I hereby certify that this correspondence is being transmitted via Facsimile Number (571) 273-0140 to the United States Patent and Trademark Office, on the date indicated above.</i>		
Signature :		
Printed Name :	Lhet Chuakay	

The information contained in this facsimile is intended solely for use by the United States Patent and Trademark Office. If this facsimile is received in error, please notify the sender and destroy the facsimile.